If you're a qualified researcher, laboratory professional, or institution setting up controlled peptide studies, getting a firm grasp on the AOD-9604 peptide before you handle a single vial matters. AOD-9604 is a synthetic fragment of human growth hormone, and its molecular behavior in laboratory models has made it a frequent subject of metabolic research. At PeptideValidation.com, the compound is supplied as a 2 mg lyophilized powder, a format chosen specifically for consistent handling, accurate weighing, and stable long-term storage in research environments.

What Is AOD-9604, Exactly?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 177-191 of the human growth hormone (hGH) sequence. It contains 15 amino acids and carries a disulfide bridge. Researchers study it primarily for its interactions with lipid metabolism pathways in controlled laboratory settings.

The name itself is a clue. AOD stands for Anti-Obesity Drug, and the compound was originally numbered 9604 during pharmaceutical development at Monash University in Australia during the 1990s. The peptide mirrors the C-terminal region of hGH, specifically residues 177 through 191.

That 15-amino-acid stretch is short enough to synthesize with high reproducibility, which is one reason it appears so often in published peptide research. The disulfide bridge between cysteine residues at positions 182 and 189 gives the molecule structural stability that a simple linear fragment would lack.

In laboratory models, researchers have examined how AOD-9604 interacts with beta-3 adrenergic receptors and lipolysis pathways. Those interactions are the subject of ongoing peer-reviewed investigation. No approved therapeutic use exists as of 2026, and the compound is classified strictly as a research-grade peptide.

For labs at PeptideValidation.com sourcing this material, the 2 mg lyophilized format ensures each research unit is pre-measured and freeze-dried, reducing pipetting variables and simplifying initial reconstitution steps when your protocol begins.

The Molecular Structure Behind the Research Interest

AOD-9604 has the molecular formula C78H123N23O23S2 and a molecular weight of approximately 1817.0 Da. Its disulfide bridge and hydrophobic C-terminal tail are structurally distinct from intact human growth hormone, which is why researchers treat it as an independent study compound rather than a simple hGH analog.

Molecular weight of roughly 1817 daltons puts AOD-9604 in the mid-range for synthetic research peptides. That size makes it amenable to standard analytical techniques without the complexity of larger biologics.

High-Performance Liquid Chromatography (HPLC) is the primary tool used to confirm purity. A quality batch typically shows a single dominant peak at greater than 98% purity by reverse-phase HPLC. Mass Spectrometry (MS) then confirms molecular identity by verifying the observed mass matches the theoretical value within accepted tolerance, usually plus or minus 0.1 Da.

The disulfide bridge deserves attention. If oxidation conditions during synthesis are poorly controlled, mixed disulfide isomers can form, reducing batch purity and reproducibility. A complete Certificate of Analysis (COA) from a reputable supplier will call out disulfide bond formation explicitly, not just report a purity number.

Storage matters too. Lyophilized AOD-9604 is generally stable at minus 20 degrees Celsius when kept dry and away from repeated freeze-thaw cycles. Once reconstituted in bacteriostatic water or another suitable vehicle, working solutions typically need refrigeration at 4 degrees Celsius and use within a defined window. Researchers should always cross-reference the batch-specific COA for the manufacturer's stability data rather than relying on general guidance alone.

How AOD-9604 Is Used in Laboratory Research

In controlled laboratory research, AOD-9604 is studied for its effects on lipid metabolism, fat cell signaling, and beta-adrenergic receptor activity. Typical study designs use in vitro cell models or rodent models, with researchers measuring biomarkers such as free fatty acid release, adipocyte response, and metabolic rate changes.

Most published studies on the AOD-9604 peptide use one of two broad experimental designs. The first is in vitro work with adipocyte cell lines, where researchers add the compound at defined concentrations and measure lipolytic responses. The second is in vivo rodent modeling, which tracks metabolic parameters over a controlled feeding period.

Concentrations in published in vitro studies have ranged from nanomolar to low micromolar, though your protocol will depend on the specific hypothesis and model system. This is not a trivial decision. Concentration errors are a leading source of irreproducible results in peptide research, which is why the 2 mg lyophilized format from PeptideValidation.com is practically useful: each unit is a defined, pre-weighed quantity that reduces calculation error at the reconstitution step.

Researchers also study AOD-9604 in the context of cartilage and bone metabolism. A handful of peer-reviewed papers from the 2000s and 2010s examined chondrocyte responses in vitro. This broadens the peptide's relevance beyond pure metabolic research and partially explains the sustained academic interest through 2026.

One important practical note: AOD-9604 is for laboratory research use only. It is not approved for human or veterinary therapeutic use. Any institutional protocol using this compound should have ethics board review where required by applicable regulations.

What to Look for in a Quality COA

A complete AOD-9604 Certificate of Analysis should include: (1) peptide sequence confirmation, (2) HPLC purity result and chromatogram, (3) MS identity confirmation with observed vs. theoretical mass, (4) batch and lot number, (5) manufacturing date and recommended storage conditions, and (6) microbial testing results where applicable.

Not all COAs are equal. Some suppliers publish a purity number with no supporting chromatogram. That's a red flag. A rigorous COA gives you the raw data to evaluate yourself, not just a pass/fail stamp.

Here's a practical checklist for reviewing an AOD-9604 COA:

• Sequence confirmation: The amino acid sequence 177-191 of hGH should be explicitly stated.
• HPLC purity: Look for a reverse-phase HPLC chromatogram alongside the numeric purity result. Values below 98% warrant scrutiny.
• Mass spec data: The observed molecular ion should match the theoretical mass within plus or minus 0.1 Da. The COA should state both numbers.
• Batch/lot number: Traceability requires a unique identifier you can reference if questions arise later.
• Manufacturing and expiry dates: Lyophilized peptides are not indefinitely stable. Confirm the batch is within its tested shelf life.
• Microbial screening: For any study involving cell culture, endotoxin and microbial contamination results are worth requesting explicitly.

Peptide Validation Certified Vendors are assessed against criteria that include transparent COA availability, independent third-party lab verification, and documented quality management systems. Checking a vendor against those standards before you place your first order is a faster route to reliable results than troubleshooting bad batches after the fact.

Reconstitution and Handling in the Lab

To reconstitute AOD-9604 lyophilized powder, researchers typically add sterile bacteriostatic water or an appropriate aqueous buffer slowly along the vial wall, then gently swirl rather than vortex, avoiding foam. A 2 mg vial dissolved in 2 mL of solvent produces a 1 mg/mL (approximately 0.55 mM) working stock that can be aliquoted and stored at 4 degrees Celsius.

Handling lyophilized peptides correctly is one of those skills that separates clean data from noisy data. The freeze-drying process creates a fragile cake structure that dissolves easily, but aggressive handling introduces bubbles and potential degradation.

Start by removing the vial from cold storage and letting it equilibrate to room temperature for 5 to 10 minutes. This prevents condensation from forming inside the vial when you open it, which can introduce moisture and accelerate degradation.

Add your reconstitution solvent slowly, directing the stream to the vial wall rather than the peptide cake directly. Gently swirl in a circular motion. If the peptide does not dissolve fully within 60 seconds, a brief bath sonication at low power (30 seconds) usually helps. Vortexing is not recommended for any research peptide; the shear forces can disrupt secondary structure.

For the 2 mg lyophilized powder format, a common starting point is 2 mL of bacteriostatic water, yielding a 1 mg/mL stock. From there, dilute to your working concentration in the appropriate buffer for your assay. Aliquot into single-use volumes where possible to minimize freeze-thaw cycles on your working stock.

Label every aliquot with the batch number from the COA, the reconstitution date, the concentration, and the solvent used. This takes 30 extra seconds and saves significant troubleshooting time if a result looks unexpected.

Common Research Questions About AOD-9604

Researchers frequently ask whether AOD-9604 affects the GH axis at research doses, how it compares structurally to other hGH fragments, and what distinguishes high-quality batches from substandard ones. Peer-reviewed literature from Monash University and subsequent studies provide a starting framework, but batch-specific analytical data remains the gold standard for quality decisions.

A few questions come up repeatedly among researchers encountering the AOD-9604 peptide for the first time.

Does AOD-9604 activate the GH receptor? Published data suggests it does not bind the classical GH receptor with meaningful affinity at the concentrations used in most laboratory studies. The proposed mechanism runs through beta-adrenergic pathways instead. This distinction is relevant when designing assay controls.

How does it compare to fragment 176-191? You'll sometimes see AOD-9604 described interchangeably with hGH fragment 176-191. The fragments overlap almost entirely. The Monash University formulation carried a tyrosine residue at position 177 and was acetylated at the N-terminus in some preparations, producing slight mass differences. Always verify which exact sequence and modification status your batch carries by reading the COA sequence confirmation line.

What causes batch-to-batch variability? Synthesis conditions, resin quality, cleavage chemistry, and purification steps all contribute. This is why independent third-party HPLC and MS testing by the vendor, not just in-house quality checks, gives researchers stronger confidence in consistency.

Is there a published reference dose for in vitro work? Concentrations in the literature range widely. A 2009 paper by Heffernan et al. used doses in the microgram-per-kilogram range in rodent models, which translates differently to in vitro molar concentrations. Pilot dose-response experiments remain best practice before committing to a full study design.

For a deeper breakdown of the compound's history, analytical standards, and vendor selection criteria, see the full AOD-9604 research guide linked at the end of this article.

Setting Up Your Research Protocol: Key Steps

Before starting an AOD-9604 study, researchers should: (1) verify batch identity and purity via COA review, (2) confirm storage conditions match the COA specifications, (3) calculate working concentrations and prepare reconstitution volumes, (4) establish positive and negative controls, and (5) document all lot numbers in the experimental record for reproducibility.

Solid protocols start before the peptide leaves the freezer. Here is a practical sequence for labs preparing an AOD-9604 experiment.

Step 1: COA review. Pull the batch-specific COA and confirm HPLC purity, MS identity, and storage requirements before signing off on the order. If the COA is missing any of those three elements, request them from the vendor.

Step 2: Storage verification. Confirm your freezer is holding steady at minus 20 degrees Celsius. A single temperature excursion of several hours above 4 degrees Celsius can meaningfully affect lyophilized peptide stability.

Step 3: Concentration planning. Calculate the molar concentration your study requires and work backward to determine the reconstitution volume from your 2 mg starting amount. Write these calculations in your lab notebook before you open the vial.

Step 4: Controls. AOD-9604 studies benefit from a vehicle control (the same reconstitution solvent at the same volume), a positive control where available in the literature, and a time-zero baseline. Without these, your data will be difficult to interpret and harder to publish.

Step 5: Documentation. Record the vendor name, batch number, COA purity result, reconstitution date, and solvent in your experimental log. This takes under 2 minutes and is required for any publication or institutional audit trail.

Laboaratories that treat analytical documentation as a step in the experiment, not an afterthought, produce more reproducible data. That principle applies to every research peptide, and AOD-9604 is no exception.

Frequently asked questions